Newly approved does not always mean new and improved

JAMA

Volumn 299, Issue 13, 2008, Pages 1598-1600

  Anderson, Geoffrey M ^a   Juurlink, David ^a,b,c   Detsky, Allan S ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DRUG USE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HUMAN; INVESTMENT; MONEY; NOTE; OFF LABEL DRUG USE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PROFIT; ARTICLE; INFORMATION DISSEMINATION; MARKETING; PATIENT PARTICIPATION; POSTMARKETING SURVEILLANCE;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; INFORMATION DISSEMINATION; MARKETING; PATIENT PARTICIPATION; PHYSICIAN'S PRACTICE PATTERNS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 41649121737     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.299.13.1598     Document Type: Note

References (18)

1. Psaty BM, Korn D. Congress responds to the IOM drug safety report: in full. JAMA. 2007;298(18):2185-2187.
2. Schultz WB. Bolstering the FDA's drug-safety authority. N Engl J Med. 2007;357(22):2217-2219.
3. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007;4(4):e134.
4. Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med. 2007;167(7):676-683.
5. Mamdani M, Rochon P, Laupacis A, Anderson G. Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. CMAJ. 2002;167(10):1125-1126.
6. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954-959.
7. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxgenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475-481.
8. Mamdani M, Warren L, Kopp A, et al. Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario. CMAJ. 2006;175(12):1535-1538.
9. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. http://www.fda.gov/cder/drug/advisory/ antipsychotics.htm. Accessed February 25, 2008.
10. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ. 2004;329(7457):75-79.
11. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781-788.
12. Polinski JM, Wang PS, Fischer MA. Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Aff (Millwood). 2007;26(3):750-760.
13. Bronskill SE, Anderson GM, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc. 2004;52(5):749-755.
14. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-632.
15. Gill SS, Bronskill SE, Norman SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-786.
16. Report of the expert advisory panel on the safety of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs). http://www.hc-sc.gc.ca/dhp-mps/ prodpharma/activit/sci-consult/cox2/sap_report_gcs_rapport_cox2_e.html. Accessed February 25, 2008.
17. US Food and Drug Administration. Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk. J Pain Palliat Care Pharmacother. 2005;19(4):83-96.
18. O'Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2007;(4):CD000409.